These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 22703804)

  • 21. The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans retinoic acid.
    Coffey DC; Kutko MC; Glick RD; Butler LM; Heller G; Rifkind RA; Marks PA; Richon VM; La Quaglia MP
    Cancer Res; 2001 May; 61(9):3591-4. PubMed ID: 11325825
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
    Qian DZ; Wang X; Kachhap SK; Kato Y; Wei Y; Zhang L; Atadja P; Pili R
    Cancer Res; 2004 Sep; 64(18):6626-34. PubMed ID: 15374977
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vorinostat synergizes with ridaforolimus and abrogates the ridaforolimus-induced activation of AKT in synovial sarcoma cells.
    Morgan SS; Cranmer LD
    BMC Res Notes; 2014 Nov; 7():812. PubMed ID: 25406429
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-tumor activity of N-hydroxy-7-(2-naphthylthio) heptanomide, a novel histone deacetylase inhibitor.
    Kim DH; Lee J; Kim KN; Kim HJ; Jeung HC; Chung HC; Kwon HJ
    Biochem Biophys Res Commun; 2007 Apr; 356(1):233-8. PubMed ID: 17353008
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic blockade of insulin-like growth factor-1 receptor via recombinant adenovirus in lung cancer can be enhanced by the histone deacetylase inhibitor, vorinostat.
    Park MY; Kim DR; Eo EY; Lim HJ; Park JS; Cho YJ; Yoon HI; Lee JH; Lee CT
    J Gene Med; 2013; 15(3-4):115-22. PubMed ID: 23413016
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The efficacy of combination therapy using adeno-associated virus--interferon beta and trichostatin A in vitro and in a murine model of neuroblastoma.
    Hamner JB; Sims TL; Cutshaw A; Dickson PV; Rosati S; McGee M; Ng CY; Davidoff AM
    J Pediatr Surg; 2008 Jan; 43(1):177-82; discussion 182-3. PubMed ID: 18206478
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cooperation of the HDAC inhibitor vorinostat and radiation in metastatic neuroblastoma: efficacy and underlying mechanisms.
    Mueller S; Yang X; Sottero TL; Gragg A; Prasad G; Polley MY; Weiss WA; Matthay KK; Davidoff AM; DuBois SG; Haas-Kogan DA
    Cancer Lett; 2011 Jul; 306(2):223-9. PubMed ID: 21497989
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting histone deacetylases: development of vorinostat for the treatment of cancer.
    Richon VM
    Epigenomics; 2010 Jun; 2(3):457-65. PubMed ID: 22121904
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery of a tetrahydroisoquinoline-based hydroxamic acid derivative (ZYJ-34c) as histone deacetylase inhibitor with potent oral antitumor activities.
    Zhang Y; Fang H; Feng J; Jia Y; Wang X; Xu W
    J Med Chem; 2011 Aug; 54(15):5532-9. PubMed ID: 21714538
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of vorinostat: current applications and future perspectives for cancer therapy.
    Richon VM; Garcia-Vargas J; Hardwick JS
    Cancer Lett; 2009 Aug; 280(2):201-10. PubMed ID: 19181442
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumor proliferation.
    Park JH; Jung Y; Kim TY; Kim SG; Jong HS; Lee JW; Kim DK; Lee JS; Kim NK; Kim TY; Bang YJ
    Clin Cancer Res; 2004 Aug; 10(15):5271-81. PubMed ID: 15297431
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Histone deacetylase inhibition restores cisplatin sensitivity of Hodgkin's lymphoma cells.
    Kewitz S; Bernig T; Staege MS
    Leuk Res; 2012 Jun; 36(6):773-8. PubMed ID: 22424710
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined targeting of perivascular and endothelial tumor cells enhances anti-tumor efficacy of liposomal chemotherapy in neuroblastoma.
    Loi M; Marchiò S; Becherini P; Di Paolo D; Soster M; Curnis F; Brignole C; Pagnan G; Perri P; Caffa I; Longhi R; Nico B; Bussolino F; Gambini C; Ribatti D; Cilli M; Arap W; Pasqualini R; Allen TM; Corti A; Ponzoni M; Pastorino F
    J Control Release; 2010 Jul; 145(1):66-73. PubMed ID: 20346382
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Histone Deacetylase (HDAC) Inhibition Induces IκB Kinase (IKK)-dependent Interleukin-8/CXCL8 Expression in Ovarian Cancer Cells.
    Gatla HR; Zou Y; Uddin MM; Singha B; Bu P; Vancura A; Vancurova I
    J Biol Chem; 2017 Mar; 292(12):5043-5054. PubMed ID: 28167529
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo.
    Luong QT; O'Kelly J; Braunstein GD; Hershman JM; Koeffler HP
    Clin Cancer Res; 2006 Sep; 12(18):5570-7. PubMed ID: 17000694
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of PAT-1102, a novel, potent and orally active histone deacetylase inhibitor with antitumor activity in cancer mouse models.
    Hiriyan J; Shivarudraiah P; Gavara G; Annamalai P; Natesan S; Sambasivam G; Sukumaran SK
    Anticancer Res; 2015 Jan; 35(1):229-37. PubMed ID: 25550555
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potential anti-cancer activity of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA), a histone deacetylase inhibitor, against breast cancer both in vitro and in vivo.
    Park KC; Kim SW; Park JH; Song EH; Yang JW; Chung HJ; Jung HJ; Suh JS; Kwon HJ; Choi SH
    Cancer Sci; 2011 Feb; 102(2):343-50. PubMed ID: 21159061
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Investigational histone deacetylase inhibitors for non-Hodgkin lymphomas.
    Watanabe T
    Expert Opin Investig Drugs; 2010 Sep; 19(9):1113-27. PubMed ID: 20649502
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of histone deacetylase inhibitor valproic acid on the anticancer effect of etoposide on neuroblastoma cells.
    Groh T; Hrabeta J; Poljakova J; Eckschlager T; Stiborova M
    Neuro Endocrinol Lett; 2012; 33 Suppl 3():16-24. PubMed ID: 23353839
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo.
    Sanchez E; Shen J; Steinberg J; Li M; Wang C; Bonavida B; Chen H; Li ZW; Berenson JR
    Leuk Res; 2011 Mar; 35(3):373-9. PubMed ID: 20650529
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.